Get the Stockscreener App
3.69
3.07%
0.11
Pre-market:
3.78
0.09
+2.44%
Indaptus Therapeutics Inc stock is traded at $3.69, with a volume of 376.54K.
It is up +3.07% in the last 24 hours and up +132.08% over the past month.
Indaptus Therapeutics Inc is a clinical biotechnology company that has developed a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. Its approach is based on the hypothesis that efficient activation of both innate and adaptive immune cells and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system activating signals that can be administered safely intravenously. Its patented technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria, designed to have reduced i.v. toxicity, but largely uncompromised ability to prime or activate many of the cellular components of innate and adaptive immunity. Its candidate, Decoy20 is for patients with solid tumors.
See More
Previous Close:
$3.58
Open:
$3.62
24h Volume:
376.54K
Relative Volume:
0.41
Market Cap:
$417.86M
Revenue:
-
Net Income/Loss:
$-18.86M
P/E Ratio:
-0.2298
EPS:
-16.054
Net Cash Flow:
$-17.68M
1W Performance:
+75.71%
1M Performance:
+132.08%
6M Performance:
+59.74%
1Y Performance:
+1,036%
1-Day Range:
$3.5005
$4.1699
1-Week Range:
$1.93
$4.1699
52-Week Range:
$0.2701
$13.40
Indaptus Therapeutics Inc Stock (INDP) Company Profile
Name
Indaptus Therapeutics Inc
Sector
Industry
Phone
(646) 427-2727
Address
3 COLUMBUS CIRCLE, NEW YORK
Compare INDP vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INDP
Indaptus Therapeutics Inc
|
3.69 | 417.86M | 0 | -18.86M | -17.68M | -16.05 |
VRTX
Vertex Pharmaceuticals Inc
|
450.46 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.98 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
884.20 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
287.80 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
160.06 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Indaptus Therapeutics Inc Stock (INDP) Latest News
INDP Q4 2025 Earnings: EPS Misses Estimates Amid Continued R&D InvestmentNet Income Trends - newsline.com
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
INDP Q4 2025 Earnings: EPS Misses Estimates, Stock Tumbles 42.62%Quarterly Earnings Report - newsline.com
Indaptus Therapeutics (INDP) Plunges 42% as Selling Pressure IntensifiesUp Down Volume - newsline.com
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
Indaptus Therapeutics, Inc. Files Form 8-K Announcing CEO Change – Junyi Dai Appointed CEO - Minichart
Indaptus Therapeutics Announces Recent Board and Leadership Changes - TipRanks
Indaptus Therapeutics directors David E. Lazar and Avraham Ben-Tzvi resign; Walt A. Linscott steps down as COO - TradingView
Leadership shifts at Indaptus Therapeutics (NASDAQ: INDP) as directors and COO exit - Stock Titan
Indaptus Therapeutics (INDP) Jumps 53.8% Amid Heavy Volume as Investors Focus on Financing/strategic-option Uncertainty - Moomoo
Indaptus Therapeutics (INDP) jumps 53.8% amid heavy volume as investors focus on financing/strategic-option uncertainty - Quiver Quantitative
INDP Q4 2025 Earnings: EPS Misses Estimates Amid No Revenue; Stock Surges Over 114%Revenue Beat Analysis - newsline.com
INDP - Finviz
INDP Q4 2025 Earnings: Wider-Than-Expected Loss as Clinical-Stage Biotech Focuses on Pipeline MilestonesMargin Expansion Trends - newsline.com
Indaptus Therapeutics Drops on Cash Runway Worries - Bez Kabli
Indaptus Therapeutics Inc. (INDP) Plunges 9.8% as Shares Approach Key Support ZoneGap Down Bounce Plays - Newser
INDP Q4 2025 Earnings: EPS Misses Estimates as Pre-Clinical Costs Continue, Stock Declines 9%Revenue Growth Outlook - newsline.com
Indaptus Therapeutics Q4 2025 Earnings: EPS Misses Estimates on Minimal Revenue, Stock SurgesFree Cash Flow Trends - The Legal Advocate
Indaptus Therapeutics Inc. (INDP) Q4 2025 Earnings: Deeper Loss, Yet Shares Surge on Pipeline ProgressRevenue Warning Signal - Newser
Indaptus Therapeutics (INDP) Surges 15%: Biotech Stock Breaks Above Key ResistanceMarket Hype Signals - Newser
Earnings Scheduled For May 15, 2026 - Sahm
Indaptus Therapeutics, Inc. Reports Substantial Doubt About Going Concern and Highlights Key Risks in Q1 2026 10-Q Filing - Minichart
Indaptus Therapeutics Reports Q1 2026 Financial Results, Management Changes, and Strategic Review Amid Cash Constraints - Minichart
Indaptus Therapeutics reassesses decoy platform as cash dwindles - grafa.com
Indaptus Therapeutics Q1 Financial Analysis - Intellectia AI
Indaptus Therapeutics Releases Q1 2026 Financial Results - AlphaStreet
Indaptus Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Indaptus Therapeutics (NASDAQ: INDP) cuts R&D, warns on cash runway - Stock Titan
Cash drops at Indaptus (Nasdaq: INDP) as Q1 2026 loss narrows - Stock Titan
Indaptus Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update - The Manila Times
Indaptus Therapeutics Q1 net loss narrows as expenses fall - TradingView
Press Release: Indaptus Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update - Moomoo
INDP Should I Buy - Intellectia AI
TradingKey - TradingKey
INDP | Indaptus Therapeutics, Inc. Common Insider Trading - Quiver Quantitative
Indaptus Therapeutics Company Profile & Introduction - Moomoo
INDP Q1'26 Earnings: EPS estimate is (1.87) USD - TradingView
Large holders in Indaptus (INDP) revise stakes and end group status - Stock Titan
Indaptus Therapeutics (INDP) Stock: Is It a Good Entry Point | Indaptus Therapeutics misses EPS views, no revenue - newser.com
Is It a Good Entry Point | Indaptus Therapeutics misses EPS views, no revenueVerified Stock Signals - Newser
Indaptus Therapeutics Appoints Tim Ruan and Johnny Fox Arrowsmith as Independent Directors; Amendment Reflects Legal Name Change - Minichart
Indaptus Therapeutics (INDP) refreshes board with two independents as one resigns - Stock Titan
Indaptus Therapeutics (INDP) reshapes board with two new independents and one exit - Stock Titan
Indaptus Therapeutics Adds Independent Directors Amid Board Refresh - TipRanks
Indaptus Therapeutics appoints two new independent directors and announces board changes By Investing.com - Investing.com South Africa
Indaptus Therapeutics appoints two new independent directors and announces board changes - Investing.com
Indaptus Therapeutics names Tim Ruan and Yi Zhang as independent directors; Matthew McMurdo resigns - TradingView
Indaptus (INDP) director Lu Qinglai submits initial Form 3 ownership - Stock Titan
Is Indaptus Therapeutics (INDP) stock trading at a premium valuation (Momentum Building) 2026-04-20 - newsline.com
Indaptus Therapeutics (INDP) Stock: Why Automation Investment (Soars) 2026-04-18Trend Analysis - Xã Châu Thành
Sino Lion Ventures Ltd Net Worth (2026) - GuruFocus
Indaptus Therapeutics Inc Stock (INDP) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.40%
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):